MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Syndrome Nutritional and Metabolic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Have Type 2 Diabetes
18 to 65 years of age

Exclusion criteria

History of Type 1 Diabetes Mellitus
Have been treated with insulin in the past 8 weeks
On a weight loss program and have ongoing weight loss
Taking weight loss medication
Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
Have taken another investigational drug in the last 8 weeks
Have active liver disease
Have a history of major surgery involving gastric or intestinal bypass

Treatment and study plan

MK0916

Drug

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Oct 15, 2007
Registry last updated: May 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed